Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Medix Inc. (331A:JPX), powered by AI.
Medix Inc. is currently trading at ¥470. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Medix Inc. on Alpha Lenz.
Medix Inc.'s P/E ratio is 3.2.
“Medix Inc. trades at a P/E of 3.2 (undervalued) with strong ROE of 40.5%.”
Ask for details →Medix Inc. is a prominent entity within the healthcare sector, focusing on the development and distribution of pharmaceutical products across a global market. Its primary function is to deliver innovative medication solutions that address a range of medical needs, enhancing patient care and outcomes. Medix Inc. is renowned for its investment in research and development, driving advancements in drug therapies for chronic and acute conditions. The company plays a critical role in advancing healthcare technologies and is a key player in the biopharmaceutical industry, contributing to both the scientific community and healthcare market. Through strategic partnerships, Medix Inc. collaborates with healthcare professionals, research institutions, and regulatory bodies to ensure the safe and effective delivery of its products worldwide. As a significant contributor to the pharmaceutical supply chain, Medix Inc. is integral to the ongoing efforts to improve global health standards, demonstrating a commitment to innovation, quality, and sustainability.
“Medix Inc. trades at a P/E of 3.2 (undervalued) with strong ROE of 40.5%.”
Ask for details →Medix Inc. (ticker: 331A) is a company listed on JPX in the Communication Services sector (Advertising Agencies). Market cap is $3.5B.
The current price is 470 with a P/E ratio of 3.22x and P/B of 1.09x.
ROE is 40.55% and operating margin is 19.28%. Annual revenue is $4.2B.